To evaluate the immunotherapeutic outcome by risk scores, different IPS values (IPS-PD-1/PD-L1/PD-L2 positive and IPS-CTLA-4 positive) were applied as markers of the immunotherapy responses of CRC patients. This evidence concerns the gene PDCD1LG2 and colorectal carcinoma.